Drug intelligence / Profile preview

autologous dendritic cells transfected with leukemia-associated antigen RNA

Development stage: Discontinued
Lead developer: Ludwig Maximilian University of Munich
Modality: Vaccines & Immunotherapeutics, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intradermal, Intravenous

Overview

Autologous dendritic cells transfected with leukemia-associated antigen RNA is an investigational cell-based immunotherapy developed by the Hospital of Ludwig Maximilians University Munich. The therapy involves generating autologous monocyte-derived dendritic cells (DCs) ex vivo from the patient's own CD14+ monocytes, which are then transfected via electroporation with in vitro-transcribed mRNA encoding leukemia-associated antigens (LAAs), specifically Wilms' Tumor protein 1 (WT1) and Preferentially Expressed Antigen in Melanoma (PRAME). These antigen-loaded mature DCs are re-administered to the patient to stimulate an AML-specific T-cell immune response. It was evaluated in a Phase 1 clinical trial (NCT01734304) for the treatment of acute myeloid leukemia (AML) in adult patients not eligible for allogeneic stem cell transplantation.

Other names: autologous dendritic cell vaccineWT1/PRAME-transfected dendritic cells

Targets

WT1 (Wilms tumor protein)PRAME (Preferentially expressed antigen in melanoma)

Beyond the preview

Go deeper on autologous dendritic cells transfected with leukemia-associated antigen RNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on autologous dendritic cells transfected with leukemia-associated antigen RNA.

Explore the full profile